Delta Pharmaceuticals Ltd.

Versi Group, LLC

Ardent Pharmaceuticals, Inc.

Delta Pharmaceutical, Inc.

Robert W McNutt, Jr

Kwen-Jen Chang

Michael J Bishop

Hugh O Pettit

Dulce Garrido Bubacz

Ann O Davis

William Pendergast

Kestutis P Biciunas

Klim King

Michael Joseph Bishop

Mark Anthony Collins

Shyi-Tai Jan

Shy-Tai Jan

Compositions and methods for treatment of sexual dysfunctions by administering to a subject a pharmaceutical composition comprising a delta opioid receptor agonist in an amount effective to delay the onset of ejaculation in the subject during sexual stimulation.

Method of treating sexual dysfunctions with delta opioid receptor agonist compounds

Delta opioid receptor agonist compounds

A method of reducing, treating or preventing drug-mediated respiratory depression, muscle rigidity, or nausea/vomiting in an animal, incident to the administration to said animal of a mixed delta/mu opioid agonist or a respiratory depression-mediating drug, comprising administering to the animal receiving said drug an effective amount of a delta receptor agonist compound. Preferred examples of such delta receptor agonist compound include diarylmethyl piperazine compounds and diarylmethyl piperidine compounds, and pharmaceutical compositions thereof, having utility in medical therapy for reducing respiratory depression associated with certain analgesics, such as mu opiates.

Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds

A method of reducing, treating or preventing drug-mediated respiratory depression, muscle rigidity, or nausea/vomiting in an animal, incident to the administration to said animal of a mixed delta/mu opioid agonist or a respiratory depression-mediating drug, comprising administering to the animal receiving said drug an effective amount of a delta receptor agonist compound.

Methods for reducing respiratory depression and attendant side effects of mu opioid compounds

A method of reducing, treating or preventing drug-mediated respiratory depression in an animal, incident to the administration to said animal of a respiratory depression-mediating drug, comprising administering to the animal receiving said drug an effective amount of a .delta. receptor agonist compound.

Compositions and methods for reducing respiratory depression and

The present invention relates to, inter alia, methods and compositions for reducing, treating or preventing respiratory depression in an animal, using a compound of the formula: ##STR1## wherein: Ar, G, Z, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as defined in specification, or a pharmaceutically acceptable ester or salt thereof.

Compositions and methods for reducing respiratory depression

Diarylmethyl piperazine compounds having utility as exogenous receptor combinant species for binding with receptors such as delta, mu, sigma, and/or kappa receptors are disclosed. Compounds of the invention may be employed as conjugates in agonist/antagonist pairs for transductional monitoring and assays of neurotransmitter function, and also variously exhibit therapeutic utility, including mediating analgesia, and possessing utility for the treatment of diarrhea, urinary incontinence, mental illness, drug and alcohol addiction/overdose, lung edema, depression, asthma, emphysema, cough, and apnea, respiratory depression, cognitive disorders, emesis and gastrointestinal disorders.

Opioid compounds

Opioid compounds and methods for making therefor

Opioid compounds and methods for using same

Growing community of inventors

Durham, NC, United States of America

Robert W McNutt, Jr